Page 2
-
As a new mpox strain gains ground, a key drug stumbles in the clinic
Despite the disappointing results, the drug’s developer, Siga Therapeutics, said there’s more to the story.
-
Lessons from COVID: Tuskegee impacts still erode trust in healthcare, but hope shines through
A long-time leader in public health and outreach to people of color, Dr. Reed Tuckson offers the lessons he learned from the COVID pandemic and how pharma can better serve those communities.
-
BioMarin taps Amgen, Roche vets in executive reshuffle
Greg Friberg and James Sabry will take over, respectively, as heads of R&D and business development, less than a year after BioMarin named a new CEO.
-
Will the IRA squash new drugs? Those worries are likely exaggerated, studies say.
There’s no link between revenue and R&D from smaller biotechs, and that’s where most innovation comes from, according to new studies.
-
Pharma’s concerns pile up months after Supreme Court’s landmark Chevron decision
The Supreme Court case added another layer of uncertainty on the regulatory front and opened up the Inflation Reduction Act to more legal attacks.
-
Q&A
23andMe inches closer to cancer immunotherapy, guided by its genetic database
Dr. Jennifer Low, head of 23andMe’s therapeutics division, is taking the company into new territory with a potential cancer treatment that targets a unique pathway.
-
Novo plans new plant as it races to meet drug demand
The new factory, which Novo is committing some $220 million to build, will supply raw materials for the company’s chronic disease medicines.
-
BMS’ KarXT nears schizophrenia approval, but AbbVie and others wait in the wings
With fewer side effects, the new wave of upcoming drugs could improve patient adherence, and the competition for a large projected market is getting fierce.
-
The drugs hit hardest by Medicare price negotiations
The final negotiations slash drug prices between 38% and 79% for Medicare’s 2026 calendar year.
-
Medicare reveals results of drug price negotiations
The agency said the first round of pricing talks, which involved drugs like the blood thinners Eliquis and Xarelto, will result in $6 billion in savings for taxpayers.
-
Can BioNTech sustain a post-COVID mRNA pipeline? Oncology is the next hope.
The German biotech is leveraging its mRNA platforms to develop a new class of cancer treatments that are necessary to lift the company’s flagging sales.
-
Q&A // Biotech Spotlight
A biotech’s difficult journey to bring a new kind of Parkinson’s drug to patients
A series of executive turnovers at Gain Therapeutics this year precedes important early-stage Parkinson’s results that could change how the disease is treated.
-
A potential MS ‘game changer’ could bring more safety to the table — even against viruses
Immunic’s treatment has anti-inflammation, neuroprotection and antiviral effects plus a ‘benign’ safety profile that even seems to lower the risk of COVID-19 infection.
-
M&A is ready to explode, and that’s good news for pharma layoffs
Deals driven by obesity meds are fueling an M&A comeback, driving the industry to take fewer cost-cutting measures.
-
Pharma execs react to final drug price negotiations with Medicare
Here’s what the leaders of the companies with the 10 drugs in the first wave of price negotiations with Medicare said about how the new prices will impact their portfolio.
-
Market share shakeup: Big Pharma’s bestselling drugs drive industry shifts in 2024’s first half
The top drugs at each of the world’s most valuable pharma companies tell the story of just how much the industry has changed over the course of a few years.
-
Roche licenses Sangamo’s technology for another shot at Alzheimer’s drugs
Through a new deal, Roche has exclusive rights to Sangamo molecules designed to repress the gene that makes “tau,” a protein many scientists view as a main driver of Alzheimer’s.
-
Q&A
Autobahn’s road to a breakthrough depression treatment is paved with high-profile investors
The biotech boasts some Big Pharma backers that drove a $100 million fundraising effort in July to take its depression drug into a mid-stage study.
-
Biotech Spotlight
A biotech dousing ‘fires’ in the brain that plagued a bestselling author
Arialys Therapeutics is developing a precision medicine treatment for a rare autoimmune encephalitis that mimics psychosis.
-
Pfizer, GSK and Moderna execs remain optimistic about RSV vaccines despite CDC blowback
An advisory committee’s age group recommendations look like a major setback, but executives are painting a rosier picture.
-
In a Duchenne market beset by problems, Capricor data marks a bright spot
The company’s cell therapy recently showed positive results from a mid-stage trial.
-
Jim Wilson, prominent gene therapy researcher, to depart UPenn
Wilson, who founded UPenn’s gene therapy program three decades ago, will step down to start two new spinouts, Gemma Bio and Franklin Biolabs.
-
Opinion
What pharma has learned from AI
As AI tools move from hype to a daily reality at pharma companies, here are the insights users are gaining.
-
Read to lead: 6 books pharma execs swear by
From an epic, alternative reality fantasy to a ‘biography of cancer,’ these six reads have stuck with pharma execs as they navigate how to lead.
-
Pfizer’s Bourla confident in company’s obesity drug position, despite delays
The CEO noted how Pfizer's danuglipron could still be the second oral GLP-1 treatment to enter registrational tests after Lilly's orforglipron.